iquid biopsy in prostate cancer

Recruiting

• Conditions: metastasized castrate-resistant prostate cancer; prostate carcinoma; 10038364

• Registration Number: NL-OMON49655
• Lead Sponsor: Zuyderland Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 100

Inclusion Criteria

- patients with metastasized castrate-resistant prostate carcinoma (mCRPC)
- patients with metastasized hormone-sensitive prostate carcinoma (mHSPC)

Exclusion Criteria

- no other malignancies
- no biopt of the prmary tumor
- patients treated with radio-isotopes
- no informed consent

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>- relation between de absence/presence of specific mutations in blood vs<br /><br>primary tumor (with special attention to AR-V7 and BRCA 1/2)<br /><br>- response on therapie</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>- relation between de absence/presence of specific mutations in urine vs<br /><br>peripheral blood (with special attention to AR-V7 and BRCA 1/2)<br /><br>- response on therapie</p><br>